Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
UBE2D3P3 is a pseudogene of the UBE2D3 gene, which means it resembles the UBE2D3 gene but lacks protein-coding potential and biological activity. UBE2D3 (the functional gene) encodes a ubiquitin-conjugating enzyme (E2) involved in protein ubiquitination, a fundamental cellular process regulating protein degradation, cell signaling, and other functions[1][3][5]. However, UBE2D3P3 itself does not produce a functional enzyme and, therefore, has no direct role in protein ubiquitination, disease processes, or drug interactions. Key details and justification: - Pseudogene status: UBE2D3P3 is explicitly designated as a pseudogene and does not code for a functional protein. Pseudogenes are not considered therapeutic targets because they generally lack biological activity (they are typically not transcribed or translated into functional products). - No biological function: Unlike the active UBE2D3 enzyme, UBE2D3P3 does not participate in molecular pathways, signaling, or act as an enzyme, transporter, or receptor. - No drug interaction: There are no drugs that target UBE2D3P3, nor mechanisms of action, roles as biomarkers, or safety concerns relevant to this sequence. - Incorrect as a therapeutic target: UBE2D3P3 should not be considered a therapeutic target. If the intent was to refer to UBE2D3, the request should instead focus on the functional enzyme. Note: If you are interested in the functional enzyme, search for "Ubiquitin conjugating enzyme E2 D3" (UBE2D3), which is a canonical member of the E2 ubiquitin-conjugating enzyme family implicated in a variety of regulatory cellular processes, including protein degradation and signaling[1][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ubiquitin conjugating enzyme E2 D3 pseudogene 3 (UBE2D3P3).